Table IV.
Sensitivity, specificity, PPV and NPV of ROMA, HE4 and CA125 between compared groups.
| Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Groups compared | All | PM | M | All | PM | M | All | PM | M | All | PM | M |
| OC vs. benign group | ||||||||||||
| ROMA | 88.3 | 71.1 | 93.6 | 88.2 | 90.1 | 82.9 | 75.3 | 48.2 | 86.6 | 94.9 | 96.1 | 91.6 |
| HE4 | – | 65.8 | 73.0 | – | 93.8 | 94.3 | – | 58.1 | 93.9 | – | 95.4 | 74.4 |
| CA125 | 88.4 | 84.2 | 89.7 | 70.2 | 67.0 | 79.1 | 54.9 | 25.0 | 83.7 | 93.6 | 97.0 | 86.5 |
| OC vs. endometriosis | ||||||||||||
| ROMA | 88.3 | 71.1 | 93.5 | 95.0 | 95.5 | 88.9 | 95.9 | 84.4 | 99.2 | 85.8 | 90.7 | 50.0 |
| HE4 | – | 65.8 | 73.0 | – | 99.1 | 100.0 | – | 96.2 | 100.0 | – | 89.4 | 20.9 |
| CA125 | 88.4 | 84.2 | 89.7 | 41.3 | 38.7 | 77.8 | 67.1 | 32.0 | 98.3 | 72.5 | 87.7 | 35.0 |
| OC vs. teratoma tumors | ||||||||||||
| ROMA | 88.3 | 71.1 | 93.5 | 97.7 | 97.4 | 100.0 | 99.3 | 96.4 | 100.0 | 69.4 | 77.1 | 42.8 |
| HE4 | – | 65.8 | 73.0 | – | 100.0 | 100.0 | – | 100.0 | 100.0 | – | 74.1 | 15.0 |
| CA125 | 88.4 | 84.2 | 89.7 | 90.9 | 89.5 | 100.0 | 97.3 | 88.9 | 100.0 | 67.8 | 85.0 | 31.6 |
| OC vs. cystadenoma tumors | ||||||||||||
| ROMA | 88.3 | 71.1 | 93.6 | 80.6 | 88.0 | 76.2 | 91.6 | 90 | 92.1 | 73.9 | 66.7 | 80.0 |
| HE4 | – | 65.8 | 73.0 | – | 92.0 | 92.9 | – | 92.6 | 96.8 | – | 63.9 | 53.4 |
| CA125 | 88.4 | 84.2 | 89.7 | 68.7 | 76.0 | 64.3 | 87.4 | 84.2 | 88.3 | 70.8 | 76.0 | 67.5 |
| OC vs. follicular, hemorrhagic and paraovarian cysts | ||||||||||||
| ROMA | 88.3 | 71.1 | 93.6 | 85.9 | 84.9 | 88.5 | 91.7 | 72.9 | 97.5 | 80.6 | 83.6 | 74.2 |
| HE4 | – | 65.8 | 73.0 | – | 86.1 | 92.3 | – | 73.5 | 97.9 | – | 81.2 | 41.4 |
| CA125 | 88.4 | 84.2 | 89.7 | 90.2 | 84.9 | 88.5 | 94.2 | 76.2 | 97.4 | 81.4 | 90.3 | 63.9 |
| A-OC vs. benign group | ||||||||||||
| ROMA | 99.1 | 94.4 | 100.0 | 88.2 | 90.1 | 82.9 | 68.9 | 36.9 | 82.9 | 99.7 | 99.6 | 100.0 |
| HE4 | – | 88.9 | 89.9 | – | 93.8 | 94.3 | – | 47.1 | 93.0 | – | 99.3 | 91.7 |
| CA125 | 95.3 | 100.0 | 94.4 | 70.2 | 67.0 | 79.1 | 46.2 | 15.8 | 79.3 | 98.3 | 100.0 | 94.3 |
| NA-OC vs. benign group | ||||||||||||
| ROMA | 70.4 | 52.6 | 80.0 | 88.2 | 90.1 | 82.9 | 44.8 | 25.6 | 60.9 | 95.7 | 96.7 | 92.6 |
| HE4 | – | 47.4 | 31.4 | – | 93.4 | 94.3 | – | 33.3 | 64.7 | – | 96.5 | 80.5 |
| CA125 | 77.8 | 73.7 | 80.0 | 70.2 | 67.0 | 79.1 | 26.1 | 12.7 | 56.0 | 95.9 | 97.5 | 92.2 |
| OC vs. other malignant neoplasms | ||||||||||||
| ROMA | 88.3 | – | – | 57.6 | – | – | 91.1 | – | – | 50.0 | – | – |
| HE4 | – | – | – | – | – | – | – | – | – | – | – | – |
| CA125 | 88.4 | – | – | 42.2 | – | – | 88.4 | – | 42.2 | – | – | |
| OC vs. borderline ovarian tumors | ||||||||||||
| ROMA | 88.3 | 71.1 | 93.6 | 59.1 | 72.7 | 45.5 | 94.1 | 90.0 | 95.1 | 40.6 | 42.1 | 38.5 |
| HE4 | – | 65.8 | 73.0 | – | 72.7 | 58.3 | – | 89.3 | 94.9 | – | 38.1 | 17.1 |
| CA125 | 88.4 | 84.2 | 89.7 | 45.5 | 40.0 | 50.0 | 92.4 | 84.2 | 94.9 | 34.5 | 40.0 | 31.6 |
| Borderline ovarian tumors vs. benign group | ||||||||||||
| ROMA | 11.8 | 9.9 | 17.1 | 59.1 | 72.7 | 45.5 | 83.9 | 90.6 | 75.0 | 3.6 | 2.9 | 5.4 |
| HE4 | – | 6.2 | 5.7 | – | 72.7 | 58.3 | – | 85.7 | 54.6 | – | 2.9 | 6.6 |
| CA125 | 29.8 | 32.3 | 20.1 | 45.5 | 40.0 | 50.0 | 90.8 | 94.1 | 78.6 | 3.5 | 2.0 | 6.7 |
PPV, positive predictive value; NPV, negative predictive value; ROMA, Risk of Ovarian Malignancy Algorithm; HE4, human epididymis protein 4; CA125, carbohydrate antigen 125; OC, ovarian cancer; A-OC, advanced ovarian cancer; NA-OC, non-advanced ovarian cancer; PM, premenopausal; M, menopausal; -, data not available.